English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 29 January 2021, 08:00 HKT/SGT
Share:
Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40
The research demonstrated that the OX40 design enhanced the antitumor activity of CAR-T cells with the potential to overcome the challenge of treating solid tumors

HONG KONG, Jan 29, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao"), the Chief Scientist Professor Xuanming Yang published a CD20-CART-OX40 related research article on January 27, 2021, EST, on Science Translational Medicine. Professor Yang found that an independently expressed full-length OX40 not only enhanced the cytotoxicity of CAR-T cells, it also reduced the exhaustion markers, thereby maintaining their function in immunosuppressive tumor microenvironment. In mouse tumor models and in patients with metastatic lymphoma, these CAR-T cells exhibited robust amplification and antitumor activities. The findings provide an alternative option for CAR-T optimization with the potential to overcome the challenge of treating solid tumors.

LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has been developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal. On January 21, 2021, the National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.

For further information about the CD-20-CART-OX40 related research article of Professor Yang Xiaoming, please visit the website of Science Translational Medicine https://stm.sciencemag.org/content/13/578/eaba7308



Topic: Press release summary Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Global Sports Brand U.S. Polo Assn. Launches Menswear in Argentina  
May 16, 2025 09:30 HKT/SGT
Spiritual Business Guide 'Zen and Stilettos' Sells 100,000 Copies, Enters Publisher's Top-10  
May 16, 2025 07:00 HKT/SGT
TruMerit Hails Release of WHO's State of the World's Nursing Report  
May 16, 2025 07:00 HKT/SGT
Euro Manganese Announces Results of Annual General and Special Meeting  
May 16, 2025 06:29 HKT/SGT
MHI Thermal Systems Receives JSRAE Technology Award  
Thursday, May 15, 2025 7:08:00 PM
HODL 2025 opens in Dubai, advancing the Emirates' position as a global financial innovation hub  
May 15, 2025 13:33 HKT/SGT
Honda and Quemix Co-develop a New, World's First Quantum State Readout Technology  
Thursday, May 15, 2025 12:37:00 PM
International Medical and Healthcare Week Highlights Hong Kong's Strengths in Medical and Innovation  
May 15, 2025 12:33 HKT/SGT
Mitsubishi Electric Building Solutions Launches a New Projection-type Hall Lantern for Overseas Markets  
Thursday, May 15, 2025 10:00:00 AM
Hola Prime and Pro Basketball Player Karl-Anthony Towns Team up for 'Speed is Success' Campaign, Redefining Prop Trading  
May 14, 2025 22:20 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575